BioWorld

Apex Biosciences describes new PDE4B inhibitors

Apex Biosciences Pte Ltd. has identified phosphodiesterase PDE4B inhibitors reported to be useful for the treatment of cancer, neurological disorders, inflammatory bowel disease, skin inflammation, ...
Seeking Alpha

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

Curated data show expression of PDE4B above a specific measurable threshold observed in 70% of adult colitis patients and 90% of pediatric colitis patients Company is advancing lead program PALI-2108, ...
Business Insider

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ...
Seeking Alpha

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Palisade Bio (PALI), ...
Business Wire

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for ...